Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers

13:33
 
Share
 

Manage episode 475990369 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

An interview with:

Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France

PARIS, France—A clinical trial using a personalized therapeutic vaccine, that recognizes multiple genetic features of each patient’s tumor, brought durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancers, and also prevented relapse in some patients.

At the 2024 Annual Meeting of the American Association for Cancer Research, held in San Diego, California, Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory at the Institut Curie in Paris, gave the Audio Journal of Oncology the latest update on his findings with the “neoantigen vaccine”.

AACR 2024 Abstract Number: LB401

ABSTRACT TITLE: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 475990369 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

An interview with:

Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France

PARIS, France—A clinical trial using a personalized therapeutic vaccine, that recognizes multiple genetic features of each patient’s tumor, brought durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancers, and also prevented relapse in some patients.

At the 2024 Annual Meeting of the American Association for Cancer Research, held in San Diego, California, Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory at the Institut Curie in Paris, gave the Audio Journal of Oncology the latest update on his findings with the “neoantigen vaccine”.

AACR 2024 Abstract Number: LB401

ABSTRACT TITLE: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play